Moderna Reports Phase 3 Success for mRNA Flu Vaccine in Adults Aged 50 and Older

July 1, 2025

FDA Approves Roche’s Gazyva for Treatment of Active Lupus Nephritis

October 21, 2025

How Artificial Intelligence is Transforming the Healthcare Industry

April 6, 2022

Must Read

Ascidian & Lilly Pen RNA Exon Editing Agreement for Genetic Kidney Issues

June 9, 2026

Top 10 Trends Redefining the Future of Medical Affairs

June 9, 2026

Travere Licenses Civorebrutinib From Everest Medicines in Deal Worth Up to $1.14 Billion

June 9, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Early research shows that Lilly’s Verve strategy is successful in lowering cholesterol

Kailera Details Nasdaq IPO Plans to Raise Up to $528.5 Million for Obesity Drug Development

Avalyn Files for IPO to Fund Late-Stage Development of Inhaled Lung Disease Therapies

Merck Pays $20 Million Upfront to Access Quotient’s Somatic Genomics Platform for IBD Research

ADC Therapeutics’ Zynlonta Trial Results in Multiple Patient Deaths

Parabilis Plans Phase 3 Desmoid Tumor Trial for Zolucatetide as It Pursues IPO

Survodutide Tolerability In Line With Class, Boehringer Executives Say

Tango Reports Early Pancreatic Cancer Data for Vopimetostat and Daraxonrasib Combination

Ascidian & Lilly Pen RNA Exon Editing Agreement for Genetic Kidney Issues

Travere Licenses Civorebrutinib From Everest Medicines in Deal Worth Up to $1.14 Billion

After a $1.2 billion deal, Innovent announces a phase 3 victory for Takeda-partnered ADC

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

J&J MedTech presents the first Ottava surgical robot clinical cases

Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances

Top 10 Trends Redefining the Future of Medical Affairs

Top 10 Trends Redefining the Future of Medical Affairs

Top 10 Infrastructure Priorities for AI-Driven Healthcare Enterprises

Agentic AI in Pharma: The Emerging Operating Model for Pharmaceutical Innovation

Tag: Civorebrutinib

Travere Licenses Civorebrutinib From Everest Medicines in Deal Worth Up to $1.14 Billion

Editor Picks

Moderna Reports Phase 3 Success for mRNA Flu Vaccine in Adults Aged 50 and Older

FDA Approves Roche’s Gazyva for Treatment of Active Lupus Nephritis

How Artificial Intelligence is Transforming the Healthcare Industry

Must Read

Ascidian & Lilly Pen RNA Exon Editing Agreement for Genetic Kidney Issues

Top 10 Trends Redefining the Future of Medical Affairs

Travere Licenses Civorebrutinib From Everest Medicines in Deal Worth Up to $1.14 Billion

Hot Topics

About Us

Follow Us